Latest News- Glioblastoma Multiforme Treatment Market: Hospitals is expected to lead the End-user segment during 2024-2028

The Glioblastoma Multiforme Treatment Market is being driven by Increasing incidence of glioblastoma multiforme

The Glioblastoma Multiforme Treatment Market is expected to grow at a CAGR of 8.2% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 1362 million. The glioblastoma multiforme (GBM) treatment market is witnessing significant growth due to the escalating research and development activities. The urgent requirement for more effective therapies, given the limited success of traditional treatments, is driving this trend. Innovative approaches, such as DCVax-L, a personalized cancer vaccine utilizing dendritic cells to stimulate an immune response against GBM, have demonstrated promising results in phase III clinical trials for extending survival in patients with newly diagnosed or recurrent GBM. Furthermore, novel strategies like Tumor Treating Fields (TTF), which employ alternating electric fields to disrupt tumor cell division, are gaining traction as non-invasive treatment options. These advancements underscore the market's potential for substantial growth. 

Get more information on Glioblastoma Multiforme Treatment Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• End-user
  • Hospitals
  • Clinics
  • Ambulatory surgical centers
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing incidence of glioblastoma multiforme
• Favorable government initiatives for glioblastoma multiforme
• Increasing geriatric population

However, the market also witnesses some limitations, which are as follows:

• Adverse effects associated with treatments
• High cost of drug development
• Stringent regulations

Benefits of Buying Global Glioblastoma Multiforme Treatment Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Glioblastoma Multiforme Treatment Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Glioblastoma Multiforme (GBM) treatment market is witnessing significant advancements with various innovative therapies. These include focused ultrasound, proton beam therapy, car T-cell therapy, oncolytic viruses, and nanoparticle drug carriers. Research is ongoing into immune checkpoint inhibitors, signal transduction pathways, miRNA expression, methylation markers, tumor infiltrating lymphocytes, PD-L1 expression, tumor vascularity, receptor tyrosine kinases, and drug metabolism enzymes. Cell signaling pathways, cell death pathways, DNA damage response, brain metastases, tumor recurrence, radiomics analysis, treatment efficacy, and survival benefit are also being explored. Neurocognitive function, patient selection criteria, treatment sequencing, complementary therapies, symptom management, palliative care, clinical outcome measures, adverse events, treatment toxicity, performance status, functional MRI, and diffusion tensor imaging are essential considerations in GBM treatment.

Market Research Overview

The Glioblastoma Multiforme (GBM) Treatment Market is a significant segment of the global pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of various types of drugs, including generics, non-generics, and veterinary drugs. Key growth drivers for this market include advancements in tumor microenvironment understanding, innovative therapies such as oncolytic virotherapy and targeted drug delivery, and the potential for enhanced immunotherapy responses. Technavio projects the global pharmaceuticals market size, which includes the revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, will be propelled by demographic shifts, with the aging population in the US and Europe projected to reach nearly one-quarter by 2050 and 2030, respectively. This demographic trend, coupled with the increasing prevalence of cancer and neurological disorders, will create significant demand for advanced GBM treatments. Radiation therapy and chemotherapy remain common treatment modalities, but chemotherapy resistance poses a significant challenge, necessitating the development of novel therapeutic approaches.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/